Early Phase 2a data suggest the IPF therapy GRI-0621 alters gene activity tied to inflammation, scarring, and tissue repair.

“She never wanted anyone to have to naively be in pain without answers," Dern tells PEOPLE of her mother, who died in November 2025 Bailey Richards is a writer-reporter at PEOPLE. She has been working ...

Environmental factors including temperature, humidity, air quality, and seasonal changes can significantly impact idiopathic pulmonary fibrosis (IPF). These triggers can exacerbate symptoms and lead ...

Please provide your email address to receive an email when new articles are posted on . Nerandomilast is the first oral preferential phosphodiesterase 4B inhibitor approved for progressive pulmonary ...

Barreling toward the end of its cash runway, GRI Bio has shared phase 2a data in idiopathic pulmonary fibrosis (IPF) and made the case for further development of its potentially disease-modifying ...

If you have scarring in your lungs, you may have been diagnosed with pulmonary fibrosis. When the reason for this scarring is unknown, your condition is called idiopathic pulmonary fibrosis (IPF). You ...

Tivardi Therapeutics (NASDAQ:TVRD) is down ~85% in Monday trading after reporting that preliminary results from a phase 2 trial of TTI-101 in idiopathic pulmonary fibrosis showed significantly higher ...

Please provide your email address to receive an email when new articles are posted on . The FDA based nerandomilast’s approval on results from two trials, one of which was the FIBRONEER-IPF trial.

What Is Jascayd, and Why Does It Matter? Jascayd (nerandomilast) is a new oral medicine approved to treat idiopathic pulmonary fibrosis (IPF) in adults. IPF is a rare and serious condition that causes ...

Credit: Boehringer Ingelheim. Nerandomilast reduces the expression of pro-fibrotic growth factors and inflammatory cytokines, commonly overexpressed in IPF. Findings showed nerandomilast led to a ...

The approval is the first in more than a decade for an idiopathic pulmonary fibrosis treatment. The FDA has approved nerandomilast (Jascayd; Boehringer Ingelheim) for the treatment of adults with ...